Tesamorelin vs Ipamorelin
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Egrifta, Egrifta WR
An FDA-approved GHRH analog used to reduce excess abdominal fat in HIV-infected patients with lipodystrophy. New F8 formulation (Egrifta WR) approved March 2025 allows weekly reconstitution vs daily.
Also: IPAM, NNC 26-0161
A selective growth hormone secretagogue that stimulates GH release without significantly affecting cortisol or prolactin. Considered one of the safest GHRPs.
Key Comparison Insights
- Tesamorelin is FDA approved, while Ipamorelin remains in research stages.
- Both peptides belong to the Growth Hormone category, suggesting similar primary applications.
- Tesamorelin has stronger research evidence (FDA Approved) compared to Ipamorelin (Human Trials).
Detailed Comparison
| Attribute | Tesamorelin | Ipamorelin |
|---|---|---|
| Category | Growth Hormone | Growth Hormone |
| FDA Status | FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Tesamorelin is a stabilized analog of human GHRH that stimulates the pituitary to release growth hormone. It specifically reduces visceral adipose tissue (VAT) while having minimal effect on subcutaneous fat, likely through GH-mediated lipolysis. | Ipamorelin binds to ghrelin receptors (GHSR) in the pituitary gland, triggering growth hormone release. Unlike other GHRPs, it does not stimulate significant ACTH, cortisol, prolactin, or aldosterone release, making it highly selective for GH. |
| Common Dosing | 2 mg daily (F8: 1.28 mg daily) Once daily | 200-300 mcg 2-3x daily 2-3x daily |
| Administration | Subcutaneous injection | Subcutaneous injection |
| Typical Duration | Indefinite for approved indication | 8-12 weeks typical |
| Best Time to Take | Before bed (fasted) | Before bed or morning (fasted) |
Possible Side Effects May vary by individual |
|
|
| Research Summary | FDA approved based on trials showing 15-20% reduction in visceral adipose tissue over 26 weeks. March 2025: FDA approved new F8 formulation (Egrifta WR) with weekly reconstitution, reducing patient burden. CROI 2025 data highlighted limitations of BMI for cardiovascular risk assessment in HIV patients. | Phase II trials for postoperative ileus showed good safety but failed to meet efficacy endpoints and were discontinued. Research demonstrates dose-dependent GH release with minimal side effects, improved bone density in postmenopausal women, and potential benefits for muscle mass and recovery. |
Frequently Asked Questions: Tesamorelin vs Ipamorelin
What is the difference between Tesamorelin and Ipamorelin?
Tesamorelin is a growth hormone peptide that an fda-approved ghrh analog used to reduce excess abdominal fat in hiv-infected patients with lipodystrophy. new f8 formulation (egrifta wr) approved march 2025 allows weekly reconstitution vs daily. Ipamorelin is a growth hormone peptide that a selective growth hormone secretagogue that stimulates gh release without significantly affecting cortisol or prolactin. considered one of the safest ghrps. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Tesamorelin or Ipamorelin?
Neither is universally "better" - the choice depends on your specific goals. Tesamorelin is typically used for growth hormone purposes, while Ipamorelin is used for growth hormone. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Tesamorelin and Ipamorelin be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Tesamorelin and Ipamorelin together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.